BACKGROUND: Patients with myelodysplasia may have autoimmune manifestations (AIM). Interferon regulatory factor-1 (IRF-1) is a transcription factor involved in interferon signalling, leukaemogenesis, and the development of the immune system. OBJECTIVES: To determine whether IRF-1 is implicated in the pathophysiology of AIM in myelodysplasia. METHODS: 14 patients with myelodysplasia were studied, seven with AIM and seven without. Five patients with vasculitis and seven normal subjects served as controls. The expression of IRF-1 was studied in bone marrow mononuclear cells taken from patients and controls, using a relative quantitative reverse transcriptase polymerase chain reaction. RESULTS: A 10-fold reduction in full length IRF-1 mRNA was detected in the myelodysplasia patients without AIM compared with the normal controls. In contrast, the group with AIM had increased IRF-1 transcripts, to a level almost equal to that observed in patients with vasculitis and normal controls. CONCLUSIONS: Myelodysplasia patients without IRF-1 expression had a decreased incidence of AIM. Thus the absence of IRF-1 transcription factor appears to protect against the development of autoimmunity in myelodysplasia.
BACKGROUND:Patients with myelodysplasia may have autoimmune manifestations (AIM). Interferon regulatory factor-1 (IRF-1) is a transcription factor involved in interferon signalling, leukaemogenesis, and the development of the immune system. OBJECTIVES: To determine whether IRF-1 is implicated in the pathophysiology of AIM in myelodysplasia. METHODS: 14 patients with myelodysplasia were studied, seven with AIM and seven without. Five patients with vasculitis and seven normal subjects served as controls. The expression of IRF-1 was studied in bone marrow mononuclear cells taken from patients and controls, using a relative quantitative reverse transcriptase polymerase chain reaction. RESULTS: A 10-fold reduction in full length IRF-1 mRNA was detected in the myelodysplasiapatients without AIM compared with the normal controls. In contrast, the group with AIM had increased IRF-1 transcripts, to a level almost equal to that observed in patients with vasculitis and normal controls. CONCLUSIONS:Myelodysplasiapatients without IRF-1 expression had a decreased incidence of AIM. Thus the absence of IRF-1 transcription factor appears to protect against the development of autoimmunity in myelodysplasia.
Authors: D A Bloch; B A Michel; G G Hunder; D J McShane; W P Arend; L H Calabrese; S M Edworthy; A S Fauci; J F Fries; R Y Leavitt Journal: Arthritis Rheum Date: 1990-08
Authors: Andrea Kröger; Mario Köster; Katharina Schroeder; Hansjörg Hauser; Peter P Mueller Journal: J Interferon Cytokine Res Date: 2002-01 Impact factor: 2.607
Authors: H Harada; T Kondo; S Ogawa; T Tamura; M Kitagawa; N Tanaka; M S Lamphier; H Hirai; T Taniguchi Journal: Oncogene Date: 1994-11 Impact factor: 9.867
Authors: N Tanaka; M Ishihara; M Kitagawa; H Harada; T Kimura; T Matsuyama; M S Lamphier; S Aizawa; T W Mak; T Taniguchi Journal: Cell Date: 1994-06-17 Impact factor: 41.582
Authors: Omar Al Ustwani; Laurie A Ford; Sheila J N Sait; Anne Marie W Block; Maurice Barcos; Carlos E Vigil; Elizabeth A Griffiths; James E Thompson; Eunice S Wang; Julian Ambrus; Meir Wetzler Journal: Leuk Res Date: 2013-05-18 Impact factor: 3.156
Authors: Christos I Maratheftis; Stavroula Giannouli; Maria P Spachidou; George Panayotou; Michael Voulgarelis Journal: Neoplasia Date: 2007-12 Impact factor: 5.715